证券代码：300109 证券简称：新开源 公告编号：2024-070 博爱新开源医疗科技集团股份有限公司 关于部分高级管理人员股份减持计划的预披露公告 高级管理人员邹晓文先生、李社刚先生保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 本公司于近日收到高级管理人员邹晓文先生、李社刚先生《股份减持计划的 告知函》，现将相关情况公告如下： 一、股东的基本情况 1.股东名称：邹晓文、李社刚 | 股东名称 | 股东职务 | 持股数量（股） | 占总股本比例（%） | | --- | --- | --- | --- | | 邹晓文 | 副总经理 | 667,904 | 0.14 | | 李社刚 | 副总经理 | 330,000 | 0.07 | | 合计 | | 997,904 | 0.21 | 2.截至本公告披露日股东持股情况： | | 减持原 | 减持 | 股份来 | 计划减持股 | 占公司总 | | | | | --- | --- | --- | --- | --- | --- | --- | --- ...

Investment Rating - Maintains an "Overweight" rating with a target price adjustment to 15.29 yuan [1][4] Core Views - Q2 performance declined sequentially, in line with expectations, with PVP sales showing stable growth over the past 8 years, solidifying its leading position [1] - Revenue for 24H1 was 735 million yuan, down 5.68% YoY, with net profit attributable to shareholders at 213 million yuan, down 18.79% YoY [4] - Q2 revenue was 340 million yuan, down 18.24% YoY and 13.83% QoQ, with net profit attributable to shareholders at 92 million yuan, down 35.64% YoY and 24.59% QoQ [4] - Gross margin and net margin for Q2 were 57.06% and 27.24%, respectively, with gross margin increasing by 3.57 pct QoQ and net margin decreasing by 3.39 pct QoQ [4] - The company continues to optimize its product structure, increasing the proportion of high-end products, and maintains a leading position in the global PVP industry [4] - New projects, including a 10,000-ton pharmaceutical-grade PVP and 2,000-ton PVP-I project, are progressing, with PVP-I revenue up 69.96% YoY in 24H1 [4] Financial Summary - Revenue for 2022A was 1,486 million yuan, increasing to 1,583 million yuan in 2023A, and is projected to reach 2,996 million yuan by 2026E [3] - Net profit attributable to shareholders was 291 million yuan in 2022A, increasing to 493 million yuan in 2023A, and is projected to reach 686 million yuan by 2026E [3] - EPS for 2022A was 0.60 yuan, increasing to 1.02 yuan in 2023A, and is projected to reach 1.42 yuan by 2026E [3] - ROE was 9.3% in 2022A, increasing to 13.9% in 2023A, and is projected to reach 13.5% by 2026E [3] - PE ratio was 18.33 in 2022A, decreasing to 10.83 in 2023A, and is projected to reach 7.79 by 2026E [3] Industry and Market Position - The company holds a leading position in the global PVP industry, ranking first in China and third globally [4] - PVP is widely used in pharmaceuticals, industrial applications, food, and daily chemicals, with the company's competitive advantage expected to strengthen [4] Growth and Expansion - The company is expanding its capacity and upgrading its product matrix, with new projects expected to drive future growth [4] - PVP-I revenue increased by 69.96% YoY in 24H1, and the company's R&D capabilities are highlighted by the growth of its Oricid series products [4] Valuation and Target Price - The target price is adjusted to 15.29 yuan based on a 2024 PE of 16X, reflecting the company's growth prospects and industry position [4] - The current price is 10.95 yuan, with a 52-week price range of 10.57-23.70 yuan [6]

Revenue and Growth - The company reported a total revenue of RMB 500 million for the first half of 2024, representing a 15% increase compared to the same period last year[3]. - The company has provided a revenue guidance of RMB 1.2 billion for the full year 2024, which reflects a projected growth of 10%[3]. - The company reported a significant increase in revenue, achieving a total of 500 million RMB for the first half of 2024, representing a 25% year-over-year growth[8]. - The company has provided a positive outlook for the second half of 2024, projecting a revenue growth of 20%[8]. - The company reported a revenue of 2726.38 million for the first half of 2024, reflecting a significant growth compared to the previous period[33]. - The company has set a future outlook aiming for a revenue growth of 15% year-over-year for the next fiscal year[33]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2024, representing a 20% year-over-year growth[43]. - The company has provided guidance for the second half of 2024, expecting revenue to grow by an additional 25% compared to the first half[44]. - The company reported a total revenue of RMB 5 billion for the first half of 2024, representing a 15% increase year-over-year[118]. User Growth and Engagement - User data indicates a growth in active users by 20%, reaching a total of 1.2 million users by June 30, 2024[3]. - User data indicates a growth in active users, reaching 1.2 million, which is a 15% increase compared to the previous year[8]. - User data indicates a rise in active users by 25%, reaching 1.5 million users in the same period[38]. - User data indicates a 30% increase in active users of the company's medical technology platforms, reaching 500,000 users by June 30, 2024[49]. - User data showed an increase in active users to 2 million, up 20% from the previous year[119]. Product Development and Innovation - New product launches in the first half of 2024 included three innovative medical devices, contributing to 30% of total sales[3]. - New product development includes advancements in molecular diagnostics, with a focus on DNA sequencing technology expected to launch by Q4 2024[7]. - New product launches are expected to drive additional revenue, with at least three new products scheduled for release in Q3 2024[33]. - New product development includes the introduction of five innovative dental care products, expected to contribute an additional 10 million RMB in revenue[38]. - New product development includes the launch of a non-medical UV lamp, which is expected to contribute an additional 5 million CNY in revenue by the end of the year[40]. - New product developments include the launch of an automated gene amplification device, which is expected to enhance operational efficiency by 40%[49]. - New product launches include a universal sequencing reagent kit and a methylation detection sample preparation kit, both expected to enhance market competitiveness[63]. Market Expansion - The company is expanding its market presence in Southeast Asia, with plans to enter two new countries by the end of 2024[3]. - The company is expanding its market presence, targeting new regions in Southeast Asia, aiming for a 30% market share by the end of 2025[8]. - Market expansion plans include entering two new international markets by the end of 2024, targeting a 20% increase in market share[33]. - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2024[38]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[43]. - The company is expanding its market presence by entering new regions, targeting a 15% increase in market share by the end of 2024[64]. Research and Development - Research and development expenses increased by 25%, totaling RMB 100 million, focusing on advanced medical technologies[3]. - The company has invested 50 million RMB in research and development for new healthcare technologies[8]. - The company has invested in several biotech firms to strengthen its capabilities in precision diagnostics and treatment, expanding its core business areas[22]. - The company is actively investing in research and development for innovative products, particularly in the fields of dental and personal care[36]. - Research and development expenditures have increased by 10% to 150 million CNY, focusing on innovative diagnostic technologies[49]. - Research and development expenses rose significantly to CNY 35,947,173.39, an increase of 51.4% compared to CNY 23,725,240.84 in the previous year[165]. Financial Performance - The company's operating revenue for the reporting period was ¥734,804,462.96, a decrease of 5.68% compared to the same period last year[13]. - Net profit attributable to shareholders was ¥212,929,814.26, down 18.79% year-on-year[13]. - The net profit after deducting non-recurring gains and losses was ¥218,300,190.74, reflecting a decrease of 15.36% compared to the previous year[13]. - The gross margin improved to 45%, up from 40% in the previous year, reflecting better cost management[8]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY for the first half of 2024, representing a 25% year-over-year growth[51]. - The company reported a significant increase in tax expenses, which rose to CNY 39,270,942.52 from CNY 73,704,647.42 year-over-year[166]. Strategic Acquisitions - The company has completed the acquisition of a local competitor, which is expected to enhance market share by 5%[3]. - A strategic acquisition of a biotechnology firm was completed, enhancing the company's capabilities in precision medicine[8]. - The company is considering strategic acquisitions to enhance its product portfolio and market presence, with potential targets identified[33]. - A strategic acquisition of a local competitor is anticipated to enhance the company's product portfolio and increase operational efficiency, expected to close by Q4 2024[38]. - The company has initiated a strategic acquisition of a smaller biotech firm, which is anticipated to contribute an additional 200 million CNY in annual revenue starting in 2025[49]. Marketing Strategies - The company plans to implement a new digital marketing strategy aimed at increasing online sales by 40% in the next six months[3]. - The company plans to implement a new marketing strategy aimed at increasing brand awareness, with a budget allocation of 10 million RMB[8]. - A new marketing strategy has been implemented, focusing on digital channels, which is projected to increase customer engagement by 30%[33]. - The company plans to enhance its online sales platform, aiming for a 50% increase in e-commerce sales by the end of 2024[38]. - A new marketing strategy focusing on digital channels is expected to increase customer engagement and drive sales growth by 10% in the next quarter[51]. Compliance and Quality Management - The company is committed to maintaining compliance with international standards, including GMP and ISO certifications, to ensure product quality[8]. - The company emphasizes high-quality management and has obtained certifications such as the Drug Production License and GMP Certificate to ensure product quality[30]. - The company has received multiple certifications for its quality management systems, ensuring compliance with international standards[63]. Environmental and Social Responsibility - The company reported an investment of CNY 234,700 in environmental governance and protection from January 1 to June 30, 2024, along with CNY 19,700 paid in environmental protection taxes[108]. - The company has implemented measures for noise reduction through foundational vibration reduction and sound insulation[108]. - The company is committed to sustainability, with initiatives aimed at reducing operational carbon emissions by 10% in the next year[63].

一、监事会会议召开情况 证券代码：300109 证券简称：新开源 公告编号：2024-068 博爱新开源医疗科技集团股份有限公司 第五届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 经审核，监事会认为：董事会编制和审议《2024 年半年度报告》及《2024 年半年度报告摘要》的程序符合法律、行政法规及中国证监会的相关规定，报告 内容 真实、准确、完整地反映了上市公司的实际情况，不存在任何虚假记载、 误导性 陈述或者重大遗漏。 表决结果：同意票 3 票；反对票 0 票；弃权票 0 票。 特此公告 博爱新开源医疗科技集团股份有限公司 监事会 2024 年 8 月 29 日 博爱新开源医疗科技集团股份有限公司（以下简称"公司"或"新开源"） 第五届监事会第九次会议于 2024 年 8 月 28 日下午在公司三楼会议室以现场加通 讯的表决方式召开，本次会议通知已于 2024 年 8 月 22 日以电子邮件形式发出。 本次会议由公司监事会主席阎重朝先生主持，应出席监事 3 名，实际出席监 事 3 名。本次会议的召集和召开程序符合《公司法》和《 ...

证券代码：300109 证券简称：新开源 公告编号：2024-065 博爱新开源医疗科技集团股份有限公司 关于 2021 年限制性股票激励计划部分限制性股票回购注销 完成的公告 本公司及其董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 重要内容提示： （一）博爱新开源医疗科技集团股份有限公司（以下简称"公司"）已于 2024 年 6 月 25 日召开 2024 年第二次临时股东大会，审议通过《关于回购注销 2021 年限制性股票激励计划部分限制性股票的议案》，决定回购注销 2021 年限制性 股票激励计划（以下简称"本激励计划"）已授予但尚未解除限售的部分限制性 股票： 1、本激励计划首次授予的激励对象中，12 名激励对象因个人原因已离职而 不符合激励资格、2 名激励对象因退休且未继续任职于公司（含子公司）而不符 合激励资格、2 名激励对象对应第三个解除限售期的个人绩效考核未达标或未完 全达标，由公司回购注销相关限制性股票共计 40.2750 万股，回购价格为 2.70 元 /股，公司已以货币资金方式支付回购价款人民币 1,087,425.00 元，资金来源为公 司自有资金 ...

证券代码：300109 证券简称：新开源 公告编号：2024-063 （二）会议出席情况 1、股东出席的总体情况： 博爱新开源医疗科技集团股份有限公司 2024 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无增加、变更、否决提案的情况。 2、本次股东大会不涉及变更前次股东大会决议。 3、本次股东大会采用现场投票、网络投票相结合的方式。 一、会议召开和出席情况 （一）会议召开情况 2024 年 6 月 7 日，博爱新开源医疗科技集团股份有限公司（以下简称"公 司"）董事会以公告形式向全体股东发出召开 2024 年第二次临时股东大会的通 知。本次会议以现场、网络相结合的方式于 2024 年 6 月 25 日下午 14:00 在河南 省博爱县文化路（东段）1888 号公司三楼会议室召开。 本次股东大会由公司董事会召集，董事长张军政先生主持，公司部分董事、 监事、高级管理人员及公司聘请的见证律师列席了会议。会议的召集、召开与表 决程序符合国家有关法律法规、部门规章和《公司章程》等规范性文件的规定。 通过现场 ...

证券代码：300109 证券简称：新开源 公告编号：2024-064 博爱新开源医疗科技集团股份有限公司 关于回购注销 2021 年限制性股票激励计划部分限制性股票 通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 博爱新开源医疗科技集团股份有限公司（以下简称"公司"）于 2024 年 6 月 25 日召开 2024 年第二次临时股东大会，审议通过《关于回购注销 2021 年限制 性股票激励计划部分限制性股票的议案》。 2021 年限制性股票激励计划首次授予的激励对象中，12 名激励对象因个人 原因已离职而不符合激励资格、2 名激励对象因退休且未继续任职于公司（含子 公司）而不符合激励资格、2 名激励对象对应第三个解除限售期的个人绩效考核 未达标或未完全达标，由公司回购注销相关限制性股票，共计 40.2750 万股，回 购价格为 2.70 元/股，本次限制性股票的回购资金来源为公司自有资金。具体内 容详见公司在巨潮资讯网披露的相关公告。 E-mail：board.sec@nkygroup.cn 特此公告 公司具体联系方式如下： 公司地址：河南省 ...

北 京 大成 律师 事 务所 关 于 博 爱 新开 源医 疗 科技 集团 股 份有 限公 司 2024 年 第 二次 临 时 股 东大 会 之 法 律 意见 书 北 京 大 成 律 师 事 务 所 关于博爱新开源医疗科技集团股份有限公司 2024 年第二次临时股东大会之法律意见书 致：博爱新开源医疗科技集团股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）和中国证券监督管理委员会《上市公司 股东大会规则（2022 年修订）》（以下简称"《股东大会规则》"）等法律、法规 和其他有关规范性文件的要求，北京大成律师事务所（以下简称"本所"）接受博 爱新开源医疗科技集团股份有限公司（以下简称"公司"）的委托，指派律师参加 公司 2024 年第二次临时股东大会（以下简称"本次股东大会"）。 本所声明：本所律师仅对本次股东大会的召集程序、召开程序、召集人资格、 出席会议人员资格、表决程序及表决结果发表法律意见，并不对本次股东大会所 审议的议案、议案所涉及的数字及内容发表意见。本所律师同意将本法律意见书 随本次股东大会其他信息披露资料一并公告。 本法律 ...

证券代码：300109 证券简称：新开源 公告编号：2024-059 博爱新开源医疗科技集团股份有限公司 第五届董事会第十二次会议决议公告 本公司及其董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 博爱新开源医疗科技集团股份有限公司（以下简称"公司"或"新开源"） 第五届董事会第十二次会议于 2024 年 6 月 17 日上午在公司三楼会议室以现场 加通讯的表决方式召开，本次会议通知已于 2024 年 6 月 13 日以电子邮件形式发 出。 本次会议由公司董事长张军政先生主持，应出席董事 9 名，实际出席董事 9 名，公司部分监事和高级管理人员列席会议。本次会议的召集和召开程序符合《公 司法》和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事认真审议，会议形成了如下决议： 具体授信额度、品类、期限及其他条款要求最终以公司与金融机构签订的协 议为准，授信期限内，授信额度可循环使用。并提请董事会授权董事长或其指定 代理人在授信额度范围内与银行签署相关协议及文件。本次授权决议期限自本次 董事会审议通过之日起 1 年内。 为满足公司的经营发展资金 ...